Comparison of MALDI‐TOF mass spectrometry analysis of peripheral blood and bone marrow‐based flow cytometry for tracking measurable residual disease in patients with multiple myeloma
- 5 February 2020
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 189 (5) , 904-907
Abstract
Summary: Matrix‐assisted laser desorption ionisation time‐of‐flight mass spectrometry (MALDI‐TOF MS) may soon replace routine electrophoretic methods for monitoring monoclonal proteins in patients with multiple myeloma. To further evaluate the clinical utility of this assay, we compared the performance of MALDI‐TOF‐MS head‐to‐head with an established bone marrow‐based measurable residual disease assay by flow cytometry (Flow‐BM‐MRD), using Memorial Sloan Kettering Cancer Center’s 10‐color, single‐tube method. Our results suggest that MALDI‐TOF‐MS adds value to bone marrow‐based MRD testing and may be most useful for early detection of relapse in peripheral blood compared to current electrophoretic methods.Keywords
Funding Information
- Society of Memorial Sloan Kettering
- National Cancer Institute
This publication has 15 references indexed in Scilit:
- MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteinsClinica Chimica Acta, 2019
- Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurementsLeukemia, 2018
- Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrowBlood Advances, 2018
- High sensitivity blood-based M-protein detection in sCR patients with multiple myelomaBlood Cancer Journal, 2017
- Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple MyelomaFrontiers in Physiology, 2017
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myelomaLeukemia, 2017
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple MyelomaJAMA Oncology, 2015
- Detecting monoclonal immunoglobulins in human serum using mass spectrometryMethods, 2015
- Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal GammopathyJournal of Proteome Research, 2014